Sorafenib treatment improves hepatopulmonary: Syndrome in rats with biliary cirrhosis

Clinical Science

Volumn 124, Issue 7, 2013, Pages 457-466

  Chang, Ching Chih ^a,b   Chuang, Chiao Lin ^a,b   Lee, Fa Yauh ^a,b   Wang, Sun Sang ^a,b   Lin, Han Chieh ^a,b   Huang, Hui Chun ^a,b   Teng, Tzu Hua ^a   Hsu, Shao Jung ^a   Hsieh, Hsian Guey ^a   Lee, Shou Dong ^b,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

Angiogenesis; Hepatopulmonary syndrome; Intrapulmonary shunt; Liver cirrhosis; Sorafenib

Indexed keywords

BETA ACTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; SORAFENIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; ARTICLE; BILIARY CIRRHOSIS; BLOOD GAS ANALYSIS; BLOOD SAMPLING; BODY WEIGHT; COMMON BILE DUCT; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG DOSE REGIMEN; HEMODYNAMICS; HEPATOPULMONARY SYNDROME; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INCISION; MALE; MICROCIRCULATION; NONHUMAN; PANCREAS DUCT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRESSURE GRADIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PULMONARY SHUNT; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BENZENESULFONATES; COMMON BILE DUCT; DISEASE MODELS, ANIMAL; HEMODYNAMICS; HEPATOPULMONARY SYNDROME; LIGATION; LIVER; LIVER CIRRHOSIS, BILIARY; LIVER DISEASES; LUNG; MALE; OXYGEN; PARTIAL PRESSURE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84872241100     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20120052     Document Type: Article

References (40)

1. Lange, P. A. and Stoller, J. K. (1995) The hepatopulmonary syndrome. Ann. Intern. Med. 122, 521-529
2. Agusti, A. G., Roca, J. and Rodriguez-Roisin, R. (1996) Mechanisms of gas exchange impairment in patients with liver cirrhosis. Clin. Chest. Med. 17, 49-66
3. Fallon, M. B. and Abrams, G. (2000) Pulmonary dysfunction in chronic liver disease. Hepatology 32, 859-865
4. Zhang, J., Luo, B., Tang, L., Wang, Y., Stockard, C. R., Kadish, I., Van Groen, T., Grizzle, W. E., Ponnazhagan, S. and Fallon, M. B. (2009) Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome. Gastroenterology 136, 1070-1080
5. Schenk, P., Fuhrmann, V., Madl, C., Funk, G., Lehr, S., Kandel, O. and Müller, C. (2002) Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut 51, 853-859
6. Swanson, K. L., Wiesner, R. H. and Krowka, M. J. (2005) Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology 41, 1122-1129
7. Tieppo, J., Cuevas, M. J., Vercelino, R., Tuñón, M. J., Marroni, N. P. and González-Gallego, J. (2009) Quercetin administration ameliorates pulmonary complications of cirrhosis in rats. J. Nutr. 139, 1339-1346
8. Fernandez, M., Mejias, M., Garcia-Pras, E., Mendez, R., Garcia-Pagan, J. C. and Bosch, J. (2007) Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology 46, 1208-1217
9. Mejias, M., Garcia-Pras, E., Tiani, C., Miquel, R., Bosch, J. and Fernandez, M. (2009) Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49, 1066-1068
10. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M. et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109
11. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A. et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134
12. Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., de Oliveira, A. C., Santoro, A., Raoul, J. L., Forner, A. et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390
13. Hennenberg, M., Trebicka, J., Stark, C., Kohistani, A. Z., Heller, J. and Sauerbruch, T. (2009) Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br. J. Pharmacol. 157, 258-270
14. Reiberger, T., Angermayr, B., Schwabl, P., Rohr-Udilova, N., Mitterhauser, M., Gangl, A. and Peck-Radosavljevic, M. (2009) Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J. Hepatol. 51, 865-873
15. Chang, S. W. and O'Hara, N. (1992) Pulmonary circulatory dysfunction in rats with biliary cirrhosis. Am. Rev. Respir. Dis. 148, 798-805
16. Fallon, M. B., Abrams, G. A., Luo, B., Hou, Z., Dai, J. and Ku, D. D. (1997) The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 113, 606-614
17. Liu, L., Zhang, M., Luo, B., Abrams, G. A. and Fallon, M. B. (2001) Biliary cyst fluid from common bile duct ligated rats stimulates eNOS in pulmonary artery endothelial cells: a potential role in hepatopulmonary syndrome. Hepatology 33, 722-727
18. Luo, B., Abrams, G. A. and Fallon, M. B. (1998) Endothelin-1 in the rat bile duct ligation model of hepatopulmonary syndrome: correlation with pulmonary dysfunction. J. Hepatol. 29, 571-578
19. Gaudio, E., Barbaro, B., Alvaro, D., Glaser, S., Francis, H., Ueno, Y., Meininger, C. J., Franchitto, A., Onori, P., Marzioni, M. et al. (2006) Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology 130, 1270-1282
20. Franco, D., Gigou, M., Szekely, A. M. and Bismuth, H. (1979) Portal hypertension after bile duct obstruction: effect of bile diversion on portal pressure in the rat. Arch. Surg. 114, 1064-1067
21. Kountouras, J., Billing, B. H. and Scheuer, P. J. (1984) Prolonged bile duct ligation obstruction: a new experimental model for cirrhosis in the rat. Br. J. Exp. Pathol. 65, 305-311
22. Fallon, M. B., Abrams, G. A., McGrath, J. W., Hou, Z. and Luo, B. (1997) Common bile duct ligation in the rat: a model of intrapulmonary vasodilatation and the hepatopulmonary syndrome. Am. J. Physiol. Gastroinstest. Liver Physiol. 272, G779-G784
23. Lee, F. Y., Wang, S. S., Tsai, Y. T., Lin, H. J., Lin, H. C., Chu, C. J., Wu, S. L., Tai, C. C. and Lee, S. D. (1997) Aminoguanidine corrects hyperdynamic circulation without ameliorating portal hypertension and portal hypertensive gastropathy in anesthetized portal hypertensive rats. J. Hepatol. 26, 687-93
24. Zhang, M., Luo, B., Chen, S. J., Abrams, G. A. and Fallon, M. B. (1999) Endothelin-1 stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome. Am. J. Physiol. Gastroinstest. Liver Physiol. 277, G944-G952
25. Lee, H. B. and Blaufox, M. D. (1985) Blood volume in the rat. J. Nucl. Med. 26, 72-76
26. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254
27. Zanetta, L., Marcus, S. G., Vasile, J., Dobryansky, M., Cohen, H., Eng, K., Shamamian, P. and Mignatti, P. (2000) Expression of von Willebrand factor, an endothelial cell marker, is up-regulated by angiogenesis factors: a potential method for objective assessment of tumor angiogenesis. Int. J. Cancer 85, 281-288
28. Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Hicklin, D. J., Wu, Y., Yanase, K., Namisaki, T., Yamazaki, M. et al. (2003) Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 52, 1347-1354
29. Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F., Breitman, M. L. and Schuh, A. C. (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66
30. Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abramsson, A., Jeltsch, M., Mitchell, C., Alitalo, K., Shima, D. and Betsholtz, C. (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161, 1163-1177
31. Roberts, K. E., Kawut, S. M., Krowka, M. J., Brown, Jr, R. S., Trotter, J. F., Shah, V., Peter, I., Tighiouart, H., Mitra, N., Handorf, E. et al. (2010) Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. Gastroenterology. 139, 130-9
32. Thakker, G. D., Hajjar, D. P., Muller, W. A. and Rosengart, T. K. (1999) The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J. Biol. Chem. 274, 10002-10007
33. Gupta, K., Kshirsagar, S., Li, W., Gui, L., Ramakrishnan, S., Gupta, P., Law, P. Y. and Hebbel, R. P. (1999) VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp. Cell Res. 247, 495-504
34. Moreno-Vinasco, L., Gomberg-Maitland, M., Maitland, M. L., Desai, A. A., Singleton, P. A., Sammani, S., Sam, L., Liu, Y., Husain, A. N., Lang, R. M. et al. (2008) Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol. Genomics 33, 278-91
35. Tugues, S., Fernandez-Varo, G., Muñoz-Luque, J., Ros, J., Arroyo, V., Rodés, J., Friedman, S. L., Carmeliet, P., Jiménez, W. and Morales-Ruiz, M. (2007) Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46, 1919-1926
36. Semela, D., Das, A., Langer, D., Kang, N., Leof, E. and Shah, V. (2008) Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastroenterology 135, 671-679
37. Coriat, R., Gouya, H., Mir, O., Ropert, S., Vignaux, O., Chaussade, S., Sogni, P., Pol, S., Blanchet, B., Legmann, P. and Goldwasser, F. (2011) Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. PLoS ONE 6, e16978
38. Myung, H. J., Jeong, S. H., Kim, J. W., Kim, H. S., Jang, J. H., Yoon, H. I. and Kim, J. S. (2010) Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report. Gut Liver 4, 543-546
39. Je, Y., Schutz, F. A. and Choueiri, T. K. (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol. 10, 967-974
40. Hennenberg, M., Trebicka, J., Kohistani, Z., Stark, C., Nischalke, H. D., Krämer, B., Körner, C., Klein, S., Granzow, M., Fischer, H. P. et al. (2011) Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. Lab Invest. 91, 241-251